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A B S T R A C T
Most experts agree that folic acid supplementation is a key preconception intervention, particularly in
women with epilepsy who take anti-epileptic drugs (AEDs). Primary prevention of neural tube defect
through folic acid supplementation results in reduction of risk in an otherwise healthy population. The
current folic acid supplementation recommendation is that all women of childbearing potential be
supplemented with at least 0.4 mg of folic acid daily prior to conception and during pregnancy. It is
recommended that all women with epilepsy and of childbearing potential be supplemented with folic
acid daily prior to conception and during pregnancy. However, considering the potential signiﬁcant
drug–drug interactions between high doses of folic acid and some AEDs in patients with epilepsy and
also with the emerging evidence from animal studies that high levels of folic acid throughout gestation
may have adverse effects on fetal brain development, it is not suggested to advocate high dose folic acid
supplementation in women with epilepsy until more information is available about its appropriate, safe
and optimal dosing.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Primary prevention of neural tube defect through folic acid
supplementation results in 62% (95% CI: 49–71%) reduction of risk
in an otherwise healthy population [1]. The current folic acid
supplementation recommendation is that all women of childbear-
ing potential be supplemented with at least 0.4 mg of folic acid
daily prior to conception and during pregnancy [2]. Most experts
agree that folic acid supplementation is a key preconception
intervention, particularly in women with epilepsy who take anti-
epileptic drugs (AEDs) [3]. In this review, I will try to emphasize
that there is insufﬁcient information to address the optimal dosing
of folic acid supplementation in women with epilepsy, who take
AEDs.
2. Folic acid supplementation in women with epilepsy
In 2009, a committee assembled by the American Academy of
Neurology (AAN) reassessed the evidence related to the care of
women with epilepsy during pregnancy, including preconcep-
tional folic acid supplementation. They concluded that the risk of* Tel.: +1 816 694 0498.
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights remajor congenital malformations in the offspring of women with
epilepsy is possibly decreased by folic acid supplementation (two
adequately sensitive Class III studies) and they recommended that
preconceptional folic acid supplementation in women with
epilepsy may be considered to reduce the risk of major congenital
malformations (Level C) [3]. They also stated that ‘‘there was
insufﬁcient published information to address the dosing of folic
acid and whether higher doses offer greater protective beneﬁt to
women with epilepsy taking AEDs’’ [3]. However, women with
epilepsy are often recognized as a high risk group and guidelines
consistently recommend prescription of high doses (up to 5 mg/-
day) of folic acid supplementation in this population [4,5]. One of
the putative reasons for recommending high doses of folic acid in
women with epilepsy is probably the fact that, women taking AEDs
are at greater risk for low folate serum levels compared to the
general population [6,7]. Treatment with cytochrome P-450
enzyme-inducing AEDs (e.g., carbamazepine, phenytoin) is known
to interfere with folate metabolism [6]. Valproic acid may also
interfere with folate metabolism [7]. Gestational folate deﬁciency
has been associated with abnormal growth and development in
both experimental animal and human studies and has been
postulated as a putative mechanism for the teratogenic effects of
AEDs. In one study, blood folate levels decreased with increasing
plasma AED levels and with the number of AEDs. Low blood folate
levels before and/or early in pregnancy were signiﬁcantlyserved.
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developmental anomalies in the offspring [6]. Therefore, it is
reasonable to recommend that ‘‘preconceptional folic acid
supplementation in women with epilepsy may be considered to
reduce the risk of major congenital malformations’’ [3].
3. Other beneﬁts of folic acid supplementation
In one study of 388 pregnancies in 244 patients, pregnancies
with folic acid supplementation showed signiﬁcant reduction of
spontaneous abortion. The occurrence of a spontaneous abortion
was much lower in women taking folic acid during pregnancy. Of
women with folic acid supplementation, 9 out of 160 pregnan-
cies (5.7%) experienced spontaneous abortion. In women without
supplementation, 30 (13.2%) spontaneous abortions out of 228
pregnancies occurred. Odds ratio for spontaneous abortion was
2.6 (95% CI: 1.2–5.6, P = 0.01) for women with no folic acid
supplementation. With regard to the dosage of folic acid
supplement, the group of pregnancies with low dosage
(0.4 mg/day; n = 33) showed no spontaneous abortion. All
spontaneous abortions with concomitant folic acid supplemen-
tation occurred in the group with high folic acid supplementa-
tion dosage (5 mg/day; n = 127) [8]. In another study, the effects
of fetal AED exposure on verbal versus non-verbal abilities at 3
years of age were investigated. The authors concluded that,
verbal abilities were lower than non-verbal in children exposed
in utero to AEDs. Preconceptional folate use was associated with
higher verbal outcomes. Mean for verbal index score adjusted for
factors in the primary analysis model was 94 for children
exposed to preconceptional folate, which differed from children
not exposed (P = 0.01), who had mean of 89. Adjusted means for
non-verbal index were 102 for children exposed to preconcep-
tion folate versus 100 for those who were not exposed, which did
not differ statistically [9]. In another study, it was observed that
low dose of folate supplementation may prevent carbamazepine-
induced leukopenia or anemia in patients with epilepsy. As other
AEDs may also reduce folate levels, these drugs may also be
responsible for the development of anemia in patients with
epilepsy. This may be avoided by prophylactic administration of
folic acid to patients with epilepsy, who will be on long-term
AED treatment [10].
4. Potential adverse effects of folic acid supplementation
There are multiple case studies about drug–drug interactions
between folic acid and some of the AEDs. In one study, the effect
of folic acid (1 mg/day orally) on phenytoin steady-state
pharmacokinetics was studied in four male folate-deﬁcient
patients with epilepsy. Blood and urine samples were collected
just before and after 180 or 300 days of folic acid administration.
After the addition of folic acid, total phenytoin plasma
concentration decreased 7.5–47.6% in three of the four patients.
Ratios of urinary metabolites to parent drug increased in those
patients showing a decrease in plasma phenytoin caused by folic
acid supplementation. This indicated that a folic acid-associated
increase in phenytoin oxidative metabolism had occurred [11].
In another study, seven adult male folate-deﬁcient patients with
epilepsy on phenytoin alone were supplemented with 1 mg daily
oral folic acid. The total serum phenytoin concentration
decreased signiﬁcantly by an average of 22.6  13.0% [12]. In
one case report, serum phenytoin level of a patient who was seizure
free for 3 years on 300 mg/day phenytoin, decreased from12.4 mg/L
to 4.5 mg/L, 1 day after the addition of 5 mg/day folic acid to treat
his macrocytic anemia. He experienced two generalized tonic-
clonic seizures [13]. Pharmacokinetic studies of this interaction
strongly suggest that folic acid is a cofactor in the metabolism ofphenytoin. Higher levels of folate appear to increase the afﬁnity of
metabolizing enzymes, thus greatly increasing the efﬁciency of
phenytoin degradation [13]. Another case report, described a
patient with megaloblastic anemia who developed an increase in
seizure frequency with a reduction in carbamazepine and
phenobarbital serum levels following treatment with folic acid
[14]. Information about potential drug–drug interactions between
folic acid supplementation and new AEDs is lacking.
In addition to the above-mentioned potential drug–drug
interactions between folic acid supplementation and AEDs in
mother, folate might directly affect the developing brain of the
fetus. Normally, the placenta concentrates folic acid into the fetal
circulation; as a result the fetal levels are 2–4 times higher than the
maternal levels; fetus requires this nutrient for its rapid growth
and cell proliferation [15]. In a recent animal study, the authors
administered large doses of folic acid to rats before and during
gestation and found that their offspring had a 42% decrease in their
seizure threshold [16]. The authors used both in vivo and in vitro
rodent paradigms. In an in vivo latency-to-seizure assay they
found that intake of folic acid by pregnant rats resulted in offspring
which had seizures twice as fast as controls when challenged by a
condition which destabilized their neural activity. To further
investigate this phenomenon, they established an in vitro neuronal
culture assay system and showed that cultures grown in the
presence of functional metabolite of folic acid (4Hfolate) have a
reduced capacity to re-regulate network activity patterns follow-
ing a perturbation, a result similar in principle to their in vivo
study. Their experiments demonstrated that folic acid and its
derivatives can alter connectivity and dynamics in a way that
produces a lack of network stability or the hyperexcitability of
individual neurons [16]. They speculated that, ‘‘by virtue of its
relationship to the excitatory neurotransmitter L-glutamate, folic
acid present at continued high levels during neuronal development
causes an increase in neuronal activity. This in turn accelerates the
developmental of neuronal connectivity, which then leads to a
hyperexcitable network’’ [16]. However, these results should be
interpreted with caution. The doses used in this animal study were
substantially higher than that taken by humans (even at 5 mg/
day). Therefore, it is difﬁcult to extrapolate these data to humans.
In another animal study, the authors investigated the impact of
high folate intake on embryonic development in mice. Pregnant
mice on a control diet (CD; recommended intake of folic acid for
rodents) or folic acid-supplemented diet (FASD; 20-fold higher
than the recommended intake) were examined for post-coitum
embryonic loss and delay. Total plasma folate was 10-fold higher in
FASD compared to CD mice. The authors observed that, the FASD
was associated with embryonic delay and growth retardation.
They concluded that high folate intake may have adverse effects on
fetal mouse development [17].
5. Conclusion
Preconceptional folic acid supplementation in women with
epilepsy may be considered to reduce the risk of congenital
malformations. Therefore, it is recommended that all women with
epilepsy and of childbearing potential be supplemented with folic
acid daily prior to conception and during pregnancy. However,
considering the potential signiﬁcant drug–drug interactions
between high doses of folic acid and some AEDs in patients with
epilepsy and also with the emerging evidence from animal studies
that high levels of folic acid throughout gestation may have
adverse effects on fetal brain development, it is not suggested to
advocate high dose folic acid supplementation in women with
epilepsy until more information is available about its appropriate,
safe and optimal dosing.
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